Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mythili Shastry

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Cancer Investigation|August 10, 2010
A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancerDenise A Yardley, Davey Daniel, Michael Stipanov, et al.
Breast Cancer Research and Treatment|July 10, 2015
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancerDenise A Yardley, Dianna L Shipley, Nancy W Peacock, et al.
Clinical Breast Cancer|July 7, 2011
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancerDenise A Yardley, Eric Raefsky, Raul Castillo, et al.
Neuro-Oncology Advances|February 10, 2025
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade gliomaGerald S Falchook, James D Battiste, Amandeep Kalra, et al.
Clinical Breast Cancer|April 22, 2018
Cabazitaxel Plus Lapatinib as Therapy for HER2<sup>+</sup> Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding StudyDenise A Yardley, Lowell L Hart, Patrick J Ward, et al.
Clinical Breast Cancer|September 25, 2018
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast CancerDenise A Yardley, Dianna Shipley, John Zubkus, et al.
Journal of Neuro-Oncology|June 18, 2016
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningiomaKent C Shih, Sajeel Chowdhary, Paul Rosenblatt, et al.
Cancer Investigation|August 10, 2010
A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancerDenise A Yardley, Michael McCleod, Fred Schreiber, et al.
Breast Cancer Research and Treatment|October 29, 2015
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence scoreDenise A Yardley, Nancy W Peacock, Mythili Shastry, et al.
Clinical Breast Cancer|January 15, 2020
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast CancerDenise A Yardley, William Liggett, Mark Mainwaring, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Cancer Investigation|August 10, 2010
A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancerDenise A Yardley, Davey Daniel, Michael Stipanov, et al.
Breast Cancer Research and Treatment|July 10, 2015
Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancerDenise A Yardley, Dianna L Shipley, Nancy W Peacock, et al.
Clinical Breast Cancer|July 7, 2011
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancerDenise A Yardley, Eric Raefsky, Raul Castillo, et al.
Neuro-Oncology Advances|February 10, 2025
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade gliomaGerald S Falchook, James D Battiste, Amandeep Kalra, et al.
Clinical Breast Cancer|April 22, 2018
Cabazitaxel Plus Lapatinib as Therapy for HER2<sup>+</sup> Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding StudyDenise A Yardley, Lowell L Hart, Patrick J Ward, et al.
Clinical Breast Cancer|September 25, 2018
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast CancerDenise A Yardley, Dianna Shipley, John Zubkus, et al.
Journal of Neuro-Oncology|June 18, 2016
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningiomaKent C Shih, Sajeel Chowdhary, Paul Rosenblatt, et al.
Cancer Investigation|August 10, 2010
A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancerDenise A Yardley, Michael McCleod, Fred Schreiber, et al.
Breast Cancer Research and Treatment|October 29, 2015
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence scoreDenise A Yardley, Nancy W Peacock, Mythili Shastry, et al.
Clinical Breast Cancer|January 15, 2020
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast CancerDenise A Yardley, William Liggett, Mark Mainwaring, et al.
Pageof 3